ArticleInternational journal of clinical and health psychology : IJCHP
Visual cognition as a marker of longitudinal disease progression in Huntington's disease.
Article in International journal of clinical and health psychology : IJCHP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Visual cognitive impairment is common in Huntington's disease (HD), but its longitudinal trajectory and prognostic value remain unclear. We aimed to characterize changes in visual cognition in premanifest (preHD) and early manifest HD compared with healthy controls, and to determine whether baseline visual cognition is associated with clinical progression. Methods: A total of 148 participants (78 controls, 39 preHD, 31 early HD) underwent annual assessments at baseline, 12, and 24 months. Visual cognition was assessed using an assessment protocol focused on attention, perception/processing speed, visuospatial ability, visual memory, and visuo-executive function. Disease burden was estimated using the CAG-Age Product (CAP). Linear mixed models examined group trajectories and tested whether baseline visual cognition predicted longitudinal changes in motor function (UHDRS), global cognition (MoCA), and quality of life (GENCAT). Results: Individuals with early HD showed faster decline in visual attention and visual perception/processing speed than controls, whereas preHD participants did not differ in overall rate of decline. However, visual memory worsened significantly in preHD as individuals approached estimated onset. Baseline visual cognition strongly predicted motor progression in preHD, with all domains associated with subsequent UHDRS worsening. In early HD, lower baseline visual attention and visuospatial abilities predicted greater cognitive decline. Quality of life remained stable overall, although baseline visuo-executive functioning predicted functional worsening in preHD. Conclusions: Visual cognition may serve as a sensitive process-level marker of longitudinal change in HD, particularly in premanifest stages. Incorporating visual cognitive measures into multidomain progression models could refine early detection, stratification, and longitudinal monitoring in HD clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.